South Korea joined other countries in approving LEQEMBI® (generic lecanemab) for mild cognitive impairment, mild and early Alzheimer’s. Learn how Leqembi is treating Alzheimer’s around the world.
In a span of 40 years, why did average brain size increase and dementia rates drop? A new UC-Davis study explores environmental factors behind this silent revolution.
“People with dementia living in nursing homes and in the community were prescribed less and we did not detect negative health impacts for these groups.”
LEQEMBI® is the newest Alzheimer’s drug. It is administered in hospitals via IV. Biogen applied to the FDA for approval of a home version using an “Autoinjector”. See how it works and learn its advantages.
The newest and most promising drug to fight Alzheimer’s is Leqembi. Carolyn Davis is giving it a try. Learn about the promise, the risks and how it has restored her hope,
Scheduled to begin on May 9, 2024, six new monthly sessions are now available in this free Continuing Education Program.
People with dementia may be even more vulnerable to fraud and scams than previously thought, according to an NIA study. See the story of one victim with a happy ending. Read the research.
Galantamine treats Alzheimer’s. Artificial intelligence and biosensors may pave the way to make this drug faster and cheaper.
A long, long time ago (1930), brains were smaller. Are today’s bigger brains connected to improvements in rates of dementia?
Trontinemab is a very exciting experimental drug, showing great promise in rapidly clearing Alzheimer’s amyloid plaques from the brains of affected individuals, with remarkably little side effects.
If you couldn’t see your mashed potatoes, you probably wouldn’t eat them. That’s why what “The Red Plate Study” found was astonishing! Alzheimer’s patients eating from red plates consumed 25 percent more food than those eating from white plates. Find out why.
Learn about 2025’s newly approved or potential Alzheimer’s drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.
A new study relating to dementia-care finds that robot use is associated with increased employment and employee retention, improved productivity and a higher quality of care.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
